Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2022
SiteOne Therapeutics and Vertex enter collaboration and licensing agreement
SiteOne Therapeutics announced a strategic collaboration and licensing agreement with Vertex Pharmaceuticals to advance NaV1.7 inhibitors as non-opioid treatments for pain. SiteOne will conduct research and early preclinical development; Vertex will handle subsequent development and commercialization.
2021
FDA expands Trikafta approval to children aged 6 to 11
The FDA expanded approval of Trikafta for children aged 6 to 11 with cystic fibrosis who have certain CFTR mutations.
2021
FDA approves expanded Trikafta use for younger patients
The FDA approved expanded use of Vertex Pharmaceuticals' cystic fibrosis drug Trikafta for children aged 6 through 11 with certain mutations.
2019
FDA approves TRIKAFTA for cystic fibrosis
The U.S. Food and Drug Administration approved Vertex Pharmaceuticals' TRIKAFTA for people ages 12 and older with cystic fibrosis who have at least one F508del mutation in the CFTR gene.